PRESS RELEASE published on 03/14/2025 at 17:45, 1 year 3 months ago Informations privilégiées / Autres communiqués PHAXIAM Therapeutics lance un processus de recherche de repreneurs dans le cadre de son redressement judiciaire. Appel d'offres ouvert jusqu'au 11 avril 2025 Appel D'offres Redressement Judiciaire Repreneurs Procédure PHAXIAM Therapeutics
BRIEF published on 03/06/2025 at 18:01, 1 year 3 months ago PHAXIAM Therapeutics entre en redressement judiciaire et retarde ses résultats financiers Retard Des Résultats Financiers Administrateur Judiciaire Suspension Des Échanges Mise Sous Séquestre De PHAXIAM Défis Biotechnologiques
BRIEF published on 03/06/2025 at 18:01, 1 year 3 months ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year 3 months ago Informations privilégiées / Autres communiqués PHAXIAM annonce l'ouverture d'une procédure de redressement judiciaire et le report de la publication de ses résultats financiers 2024. La Société se place sous la protection du Tribunal de commerce de Lyon Résultats Financiers Tribunal De Commerce Redressement Judiciaire PHAXIAM Procédure
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year 3 months ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 1 year 3 months ago Suspension de la Cotation de PHAXIAM Therapeutics Euronext Paris Biopharmaceutique Suspension Cotation PHAXIAM Therapeutics Infections Résistantes
BRIEF published on 03/06/2025 at 11:45, 1 year 3 months ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
PRESS RELEASE published on 03/06/2025 at 11:40, 1 year 3 months ago Informations privilégiées / Autres communiqués PHAXIAM Therapeutics suspend sa cotation sur Euronext Paris en attendant un prochain communiqué. La société développe des traitements innovants contre les infections bactériennes Cotation Suspension Traitements Innovants PHAXIAM Therapeutics Infections Bactériennes
BRIEF published on 12/30/2024 at 17:50, 1 year 5 months ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
BRIEF published on 12/30/2024 at 17:50, 1 year 5 months ago PHAXIAM Therapeutics : résultats prometteurs de l’étude pilote PhagoDAIR PHAXIAM Therapeutics Étude PhagoDAIR Phages Anti-S. Aureus Phase II GLORIA Contrôle De L'infection
Published on 06/24/2026 at 03:15, 34 minutes ago Noram Lithium Adopts Semi-Annual Financial Reporting
Published on 06/24/2026 at 00:00, 3 hours 49 minutes ago Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/23/2026 at 23:45, 4 hours 4 minutes ago Prospect Ridge Aligns with the Market Mindset for Exclusive Live Investor Interview Discussing Game-changing 2026 Drill Programs
Published on 06/23/2026 at 23:20, 4 hours 29 minutes ago BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/23/2026 at 23:15, 4 hours 34 minutes ago EV Nickel Signs LOI Forming High-Grade Nickel Joint Venture for Shaw Dome Projects
Published on 06/24/2026 at 02:05, 1 hour 43 minutes ago FRONTERA AND KUPARI ANNOUNCE COMMENCEMENT OF STRATEGIC SALE PROCESS FOR THE JOINTLY OWNED PIEDRAS VERDES COPPER MINE COMPLEX IN SONORA, MEXICO
Published on 06/23/2026 at 22:20, 5 hours 28 minutes ago Saudi Properties Portal to Accept Applications for Foreign Real Estate Ownership
Published on 06/23/2026 at 20:15, 7 hours 33 minutes ago EQS-Adhoc: OHB SE resolves on the issue of 1,605,388 new shares representing the first tranche of the up to 8.86% capital increase with subscription rights
Published on 06/23/2026 at 18:30, 9 hours 19 minutes ago IEVA GROUP: COMPTE RENDU DE L’ASSEMBLÉE GÉNÉRALE ORDINAIRE ANNUELLE DU 23 JUIN 2026
Published on 06/23/2026 at 19:47, 8 hours 1 minute ago GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 8 hours 1 minute ago GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 8 hours 38 minutes ago GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 8 hours 38 minutes ago GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
Published on 06/23/2026 at 18:32, 9 hours 16 minutes ago Communiqué sur la demande de radiation auprès d'Euroclear des Droits à Complément de Prix
